Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic and therapeutic implications of BRAF mutations in acute myeloid leukemia.

Leukemia·2026
Same author

Biallelic germline MBD4 mutations predispose to colorectal polyposis, hypermutated AML, and schwannomas.

Familial cancer·2026
Same author

Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with Ibrutinib.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report.

Frontiers in immunology·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Phase 1 Study of KITE-222, an Autologous CLL-1-Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Video

Updated: Mar 25, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.7K

Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.

Joseph Maly1,2, James S Blachly3,4

  • 1Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.

Current Hematologic Malignancy Reports
|February 20, 2016
PubMed
Summary

Chronic lymphocytic leukemia (CLL) research has advanced cancer therapy by identifying key cellular targets. Understanding CLL biology enables the development of targeted drugs for improved oncology treatments.

Keywords:
ACP-196Chronic lymphocytic leukemiaIbrutinibIdelalisibNovel therapyTargeted therapy

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Related Experiment Videos

Last Updated: Mar 25, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.7K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The last 20 years have seen significant oncology advancements driven by cellular biology and signaling insights.
  • Chronic lymphocytic leukemia (CLL), with its slow progression, serves as a model for studying cancer biology and translating findings to other diseases.
  • Systematic analysis of CLL cell biology and signal transduction pathways has revealed critical vulnerabilities.

Purpose of the Study:

  • To review the key molecular targets in chronic lymphocytic leukemia (CLL) based on an enhanced understanding of cancer biology.
  • To discuss current and emerging therapeutic molecules targeting these vulnerabilities in CLL.
  • To highlight how CLL research informs broader cancer treatment strategies.

Main Methods:

  • Review of scientific literature on CLL biology, signaling pathways, and targeted therapies.
  • Systematic analysis of signal transduction from surface immunoglobulin to nuclear transcription factors in CLL cells.
  • Identification and categorization of key molecular targets including Bruton's tyrosine kinase (BTK), PI3K, Src, Bcl2, and CDKs.

Main Results:

  • Identification of key targets such as Bruton's tyrosine kinase (BTK), phosphatidylinositol 3-kinase (PI3K), Src, Bcl2, and cyclin-dependent kinases (CDKs) in CLL.
  • Understanding of signal transduction pathways provides a basis for rational drug targeting in CLL.
  • The indolent nature of CLL facilitates detailed biological investigation and therapeutic development.

Conclusions:

  • Targeting specific molecular vulnerabilities, such as those involving BTK, PI3K, and Bcl2, represents a rational therapeutic strategy in CLL.
  • Advances in understanding CLL cell biology have paved the way for novel, targeted therapies.
  • CLL serves as a valuable model for developing and translating targeted cancer treatments.